Global Clinical Pharmacology
Joint venture between Hospital Corp. of America and the Institute of Clinical Pharmacology established to manage clinical research using HCA hospitals. ICP will own 80% of the joint venture and contribute its worldwide medical research operations. Global, headquartered in Nashville on the HCA campus, will be headed by ICP Chairman and CEO Austin Darragh. HCA is putting up $2.6 mil. for its 20% stake.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”